Drug intelligence / Profile preview

N066 (Convalife (Shanghai))

Development stage: Unknown
Lead developer: Convalife Pharmaceutical
Modality: Small Molecules

Overview

N066 (Convalife (Shanghai)): sourced facts only. name: "CD38 small-molecule inhibitors N066 demonstrates good antitumor activity, highlighting its therapeutic potential." [DOI:10.1158/1538-7445.am2025-835]; target: "CD38 small-molecule inhibitors N066 demonstrates good antitumor activity, highlighting its therapeutic potential." [DOI:10.1158/1538-7445.am2025-835]; developer: "Convalife (Shanghai) Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2025-835]; modality: "CD38 small-molecule inhibitors N066 demonstrates good antitumor activity, highlighting its therapeutic potential." [DOI:10.1158/1538-7445.am2025-835]; stage: "In B16-F10 tumor-bearing mice, combining N066 with anti-PD-L1 therapy enhanced antitumor activity." [DOI:10.1158/1538-7445.am2025-835]

Targets

CD38 (Cluster of Differentiation 38)

Beyond the preview

Go deeper on N066 (Convalife (Shanghai)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on N066 (Convalife (Shanghai)).